TFX · Teleflex Inc

Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable March 31, 2026, to shareholders of record at the close of business on March 6, 2026. Additional information about Teleflex can be obtained from the company’s website at teleflex.com . About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™,

Announces Restructuring to Right-Size and Reduce Cost Structure Related to Announced Strategic Divestitures Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the year ended December 31, 2025. Full year 2025 continuing operations financial summary 1 GAAP revenue from continuing operations of $1,992.7 million, up 17.2% compared to the prior year period1 Adjusted revenue from continuing operations of $1,983.7 million, up 16.3% compared to the prior year period, and up 15.4% on an adjusted constant currency basis2 GAAP diluted EPS from continuing operations of $1.31, compared to $1.21 in the prior year period Adjusted diluted EPS from continuing operations of $6.98, compared to $6.42 in the prior year period 2026 continuing operations guidance summary 1 GAAP revenue growth guidance range of 14.40% to 15.40% Pro forma adjusted constant currency revenue growth guidance range of 4.50% to 5.50%3 GAAP EPS from continuing operations guidance range to $2.90

Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter 2025 financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 26, 2026. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, teleflex.com . An audio replay of the call will be available beginning at 11:00 am Eastern Time on February 26, 2026, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The conference ID is 69028. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the

Stuart Randle Appointed Interim President and CEO Board Initiates Search for Permanent CEO Dr. Stephen Klasko Appointed Chairman of the Board Company Provides Update on Preliminary Full Year 2025 Revenue Results WAYNE, Pa., Jan. 08, 2026 (GLOBE NEWSWIRE) - Teleflex Incorporated (NYSE: TFX) today announced that Stuart Randle, a member of the Company’s Board of Directors, has been appointed Interim President and Chief Executive Officer, effective immediately. Mr. Randle succeeds Liam Kelly, who departs as Chairman, President and CEO of the Company. Dr. Stephen Klasko, the Company’s Lead Director, has been named Chairman of the Board. The Board has engaged Spencer Stuart, a leading executive search firm, to assist in a comprehensive search process to identify a permanent CEO. “With the announced sale of our Acute Care, Interventional Urology and OEM businesses, Teleflex is entering its next phase as a more focused, higher-growth organization, as well as executing on the announced